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Abstract
Objective—To determine the effect of age on completion of and toxicities following treatment of 
local regionally advanced cervical cancer (LACC) on Gynecologic Oncology Group (GOG) Phase 
I–III trials.
Methods—An ancillary data analysis of GOG protocols 113, 120, 165, 219 data was performed. 
Wilcoxon, Pearson, and Kruskal-Wallis tests were used for univariate and multivariate analysis. 
Log rank tests were used to compare survival lengths.
Results—One-thousand-three-hundred-nineteen women were included; 60.7% were Caucasian, 
15% were age 60–70 years and an additional 5% were >70; 87% had squamous histology, 55% 
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had stage IIB disease and 34% had IIIB disease. Performance status declined with age (p = 0.006). 
Histology and tumor stage did not significantly differ.
Number of cycles of chemotherapy received, radiation treatment time, nor dose modifications 
varied with age. Notably, radiation protocol deviations and failure to complete brachytherapy (BT) 
did increase with age (p = 0.022 and p < 0.001 respectively).
Only all grade lymphatic (p = 0.006) and grade ≥3 cardiovascular toxicities (p= 0.019) were found 
to vary with age.
A 2% increase in the risk of death for every year increase >50 for all-cause mortality (HR 1.02; 
95% CI, 1.01–1.04) was found, but no association between age and disease specific mortality was 
found.
Conclusion—This represents a large analysis of patients treated for LACC with chemo/
radiation, approximately 20% of whom were >60 years of age. Older patients, had higher rates of 
incomplete brachytherapy which is not explained by collected toxicity data. Age did not adversely 
impact completion of chemotherapy and radiation or toxicities.
Keywords
Biomarkers; Cervical cancer; Chemoradiation
1. Introduction
The older population, typically defined as persons 65 years or older, numbered 39.6 million 
in 2009 and represented 13% of the U.S. population [1]. It is estimated that by 2030 there 
will be approximately 72 million older persons, more than twice their number in 2000, and 
persons age 65 and older are expected to represent 19% of the population [1]. Along with 
the rapid growth in the aging population comes an increased prevalence of cancer diagnosis 
within this group. Cancer of the uterine cervix is one of these malignancies with potential 
for increased incidence in this increasingly aged population.
According to the American Cancer Society, it is estimated that 12,990 women will be 
diagnosed with cervical cancer and 4120 women will die from their disease in 2016 [2]. 
Although the overall incidence of cervical cancer has declined since the introduction of 
regular cervical screening guidelines, the proportion of older women being diagnosed with 
the disease has increased. In 2007, the incidence rate of cervical cancer for women greater 
than age 50 was 10.3 per 100,000 compared to 5.1 per 100,000 for those younger than 50 
[3]. This is not unexpected given that cervical cancer is bimodal in its age related 
distribution with peaks between the ages of 30–39 and a second peak from 60 to 69 [4].
While the increase in incidence of cervical cancer with age is anticipated, the role of age in 
prognosis has not yet been determined. There are very contradictory results regarding the 
effect of age on survival. The standard of care for local advanced cervical cancer is 
concurrent chemoradiation (CCRT) plus brachytherapy. CCRT is also applicable in early-
stage cervical cancer patients not suitable for radical surgery, such as in the case of some 
older persons with multiple medical comorbidities [5].
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Studies have suggested that both overall and disease specific outcomes are poorer among 
older populations usually defined as >65. This finding, however, is likely due in large part to 
disparities in treatment rendered. Several studies demonstrate that when older patients are 
treated with standard of care therapies their outcomes are comparable to younger cohorts 
and without unacceptable increase in toxicity [4, 6–8]. Previous studies among endometrial 
cancer patients have not shown differences in complications of radiation therapy for older 
compared with younger patients [7, 9, 10]. However, cervical cancer patients differ greatly 
from those with endometrial cancer with intrinsic differences in tumor biology as well as 
significant differences in the radiation dose delivered. Cervix cancer patients are also more 
commonly of lower socioeconomic status with attendant health related challenges such as 
tobacco and substance abuse, poor nutrition, and poor social support.
It is important to evaluate age as a factor for tolerance and completion of CCRT as well as 
survival in the treatment of cervical cancer. Currently there is a paucity of prospective data 
investigating this unique topic. Kunos et al. evaluated patients treated on GOG protocol 120 
and 165 and found no difference in seriousness or frequency of treatment related sequelae 
with a cut point of 55 years of age [4]. Whether 55 is a good representation of the older 
population for cervix cancer is an outstanding question given that standard definitions start 
at age 65 or greater.
This current work is an ancillary analysis of cervical cancer patients treated with primary 
CCRT on GOG protocols 113, 120, 165 and 219 with data stratified by decade of age with a 
goal of evaluating patients ≥65. The age groups would be compared for tolerance and 
completion of CCRT including prescribed BT [11–14].
The Alliance currently incorporates specific assessments for older persons in their study 
designs. This is not routinely done for NRG and other cooperative studies, but there is an 
increasing mandate that we do so. Data gathered from this analysis will provide information 
about elderly cervical cancer patients, a vulnerable population, and may demonstrate the 
need for tailored assessments to this group including dose modifications and toxicity 
considerations.
2. Methods and statistics
The data set comprised patients from GOG-0113, 120, 165, and 219 who were evaluated and 
treated for carcinoma of the cervix.
Inclusion criteria and treatment details for each of these trials has been published previously. 
In summary, each of these trials enrolled patients with stage IIB–IVA (GOG 219 allowed 
IB2) invasive squamous, adenocarcinoma and adenosquamous cervical carcinoma treated 
with radiation with or without cisplatin containing regimens. This analysis includes those 
patients treated with cisplatin containing regimens concurrent with radiation (CCRT) [11–
14].
Stage was established by physical examination in all studies and the pathology was centrally 
reviewed although this was not a prerequisite for study initiation. In all studies, patients with 
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stage IIIA disease or those with distal vaginal involvement were excluded due to the 
complexity and required individualization of brachytherapy.
Evidence of para-aortic lymph node positivity (either pathologic or radiographic) or disease 
outside of the pelvis was exclusionary on all studies. GOG 113 and 120 required extra-
peritoneal lymph node dissection with confirmation of negative nodes for study entry [11, 
12]. GOG 165 and 219 required negative computed tomography or lymphoscintigraphy but 
did not require histologic confirmation [14]. All participating institutions obtained 
Institutional Review Board approval prior to enrolling patients and all patients had to sign 
informed consent prior to study participation.
3. Treatment received
3.1. Chemotherapy
GOG 113 was anon-randomized Phase I–II trial that treated patients with continuous 
infusion 5-FU, hydroxyurea and cisplatin. Patients received continuous infusion 5-FU over 
96 h on days 2–5 and days 30– 33 at an initial dose of 800 mg/m2/day. Cisplatin was given 4 
h before radiation at a dose of 50 mg/m2 on day 1 and 29. Patients took hydroxyurea orally 
twice weekly during external radiation. Chemotherapy was held for white blood cell (WBC) 
< 3000/µl or platelets <100,000/µl [11]. All 75 patients enrolled in GOG 113 were included 
in this ancillary analysis.
GOG 120, 165 and 219 all included patients randomly assigned to receive weekly cisplatin 
at a dose of 40 mg/m2 on day 1, 8, 15, 22, 29 and 36 during external radiation therapy. GOG 
120 also had an arm identical to the chemotherapy prescribed in GOG 113. Doses of 
cisplatin were modified for leucopenia <2500/mm3 on GOG 120, <3000 on GOG 165 and 
<1000/mm3 on GOG 219 as well as for thrombocytopenia b50,000/mm3 on GOG 120 and 
GOG 219 and b100,000/mm3 on GOG 165. Once toxicities had recovered, doses were 
resumed with pre specified dose modification [11, 13, 14]. All patients who were 
randomized to receive chemoradiation on one of these protocols were included in this 
analysis.
3.2. Radiation
GOG 113—External beam radiation was given in two field AP/PA at a dose of 4080 cGy 
for stage IIB and 5100 cGy for stage III and IV in 30 fractions. A 4-field box technique was 
permitted. The radiation source was required to be 4 MV or higher or 60Co irradiators. 
Following external beam radiation, 1 or 2 applications of LDR were given to a dose of 40 
Gy at point A for stage IIB and 30 Gy to point A for IIIB–IVA disease. HDR was not 
included in this protocol [11].
GOG 120—External beam radiation was given as a 4 field box delivered in 1.7 Gy/day 
fractions using 4 MV photos or higher. Doses ranged from 40.8 Gy for stage II disease to 
51.0 Gy for stage III/IVA disease. External beam therapy was followed by 1 or 2 
applications of intra-cavitary BT delivered via LDR. HDR was not allowed on this protocol 
[12].
Moore et al. Page 5
Gynecol Oncol. Author manuscript; available in PMC 2017 November 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
GOG 165—External beam radiation was given as a 4 field box delivered in 1.8 Gy fractions 
using 4 MV photons or higher to a dose of 45.0 Gy. Intra-cavitary radiation followed 
external beam and could include either 40 Gy to point A in 1 or 2 fractions via LDR or 30 
Gy to point A in 5 fractions if using HDR [13].
GOG 219—Patients were prescribed 41.4 to 45 Gy external beam radiation therapy 
delivered in 23 to 25 fractions of 1.8 Gy. After completion of external beam, patients 
received 35 to 43.6 Gy to point A by intra-cavitary implant with radium or its equivalent if 
treated with LDR. If HDR was used, the dose to point A was 27 to 31.5 Gy over 5 fractions 
[14].
It is worth emphasizing the changes in radiation techniques both for external beam fields and 
inclusion of HDR brachytherapy required education and quality assurance and occurred 
between the execution of GOG protocols 113/120 and GOG protocols 165/219.
Anatomic fields for pelvic radiation are defined by the GOG and include an upper margin of 
the L-5 vertebrae and a lower margin of the mid portion of the obturator foramen or the 
lowest extent of disease with a 3 cm margin for anterior and posterior radiation fields. 
Laterally the anterior and posterior radiation fields extended 1.5 to 2 cm. beyond the pelvic 
brim. For right and left lateral radiation fields, the anterior border was the pubic symphysis 
and the posterior border was the space between the S2 and S3 vertebrae. The posterior 
border was placed behind the sacrum starting with GOG 165. The superior and inferior 
margins for lateral radiation fields were the same as the anterior and posterior radiation 
fields.
Interstitial BT was not allowed on GOG protocols.
3.3. Statistical analysis
The data collected included patient demographics, clinicopathologic information, 
chemotherapy administration, radiation therapy completion, adverse events, and survival 
outcomes. Completion of brachytherapy was determined by the ratio of the mean dose to 
point A. The association of age with measures of chemoradiation tolerance, toxicity, and 
survival was evaluated. Categorical variables were compared among the various age groups 
by the Pearson chi-square test [15], and continuous variables by the Kruskal–Wallis test 
[16]. Survival was estimated using the Kaplan–Meier [17] method. The Cox proportional 
hazards model [18] was used to evaluate age and other independent prognostic factors and to 
estimate their covariate-adjusted effects on progression-free survival (PFS) and overall 
survival (OS). The association of age with toxicity counts was evaluated with the covariate-
adjusted Poisson regression model. The association of age with measures of chemoradiation 
tolerance was evaluated with the covariate-adjusted logistic regression model. The 
nonlinearity of the effect of continuous variables was assessed using restricted cubic splines. 
All statistical tests were two-tailed with the significance level set at α = 0.05. Statistical 
analyses were performed using the R programming language and environment [19].
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4. Results
4.1. Demographics
1319 patients were included in this analysis. The demographic and pathology characteristics 
of this large cohort of women treated on clinical trials with concomitant chemotherapy and 
radiation is displayed in Table 1 divided by age. In the overall cohort, the majority were 
Caucasian (61%), while 21% were Black and 12% Hispanic. Median age was 47.7 years. 
The vast majority of trial participants had squamous cell carcinoma (87.4%) and just over 
half were enrolled as stage IIB (55%). The second most common stage enrolled was IIIB at 
34%. Medicaid or uninsured comprised 41% of the cohort.
When evaluated by age, there was no difference in tumor grade, stage or histology. Not 
surprisingly, statistically significantly more women in the older age categories had Medicare 
as a payer source (p < 0.001) and more women in the older age categories were enrolled 
with poorer performance status (p = 0.006). There were statistically significant differences in 
race/ethnicity with more women ≥70 years of age being Hispanic or Asian race than as 
compared to younger groups.
4.2. Treatment received
The chemotherapy received varied by study protocol. Details of the treatments received are 
presented in Table 2 categorized by age. In the cohort as a whole, only 16% of patients 
required a chemotherapy dose modification and only 5% were delayed. The median length 
of radiation duration including brachytherapy was 57 days. The lower and upper quartiles 
were 51 and 66 days, respectively. Nineteen percent of patients required a radiation dose 
modification and 37% of the enrolled patients had either minor (21%) or major (16%) 
radiation protocol deviations. BT was not completed in 15%.
When evaluated by age, there were no statistically significant differences in number of 
cycles of chemotherapy received, need for chemotherapy dose modification, need for 
chemotherapy dose delay or completion of assigned chemotherapy. There was a trend 
towards the oldest age group (>70) receiving less mean dose to point A (p = 0.054). Mean 
dose delivered to point B varied significantly between the age groups but did not correlate 
with age (p < 0.001). Interestingly, there were significantly more major radiation protocol 
deviations among the oldest age group (27% in those ≥70 as compared to 17% in those <40; 
p = 0.022). There was also significantly less completion of BT among the oldest population 
(35% in those ≥70 as compared to 13% in those <40; p < 0.001). BT completion was 
determined by evaluating ratio of the reported dose given to point A over the planned point 
A dose. If this ratio was ≥0.85, then the dose is considered “fully acceptable” according to 
the GOG radiotherapy manual. If the ratio was <0.85, then the brachytherapy dose was 
considered incomplete.
Supplemental Table 1 summarizes the logistic regression model of the association of 
brachytherapy completion with age along with other important clinical factors including, 
insurance type, race, performance status, stage and specific GOG protocol participation. Age 
was a significant factor associated with completion of BT (p = 0.118) along with BMI (p = 
0.0112), performance status (p = 0.0016) and stage (0.0007) but not specific protocol 
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participation (p = 0.1211). Fig. 1 shows the partial effects plot of age on the log odds of BT 
completion. The increase in log odds of BT before age ≈ 50 years is not significant given the 
wide confidence intervals, but after 50 the log odds of BT appears to decrease sharply. More 
specifically, the odds of completion of BT decreased approximately 5% for each increasing 
year of age after about 50 years (OR = 0.95, 95% CI: 0.95–0.99). Age was only significant 
in the model for BT completion, not in other models evaluating measures of chemoradiation 
tolerance.
4.3. Toxicity
Toxicity data was collected and grouped by type and age category. Toxicities recorded 
included white blood count, peripheral and central neurotoxicity, other hematologic, skin, 
genitourinary, lymphatic, gastrointestinal/hepatic, pulmonary and cardiovascular toxicities as 
well as symptoms of stomatitis/pharyngitis, fever, and allergy. For toxicities of any grade ≥ 
1, there were no toxicities that varied significantly by age with the exception of lymphatic 
toxicity which occurred more frequently among the oldest age group (10% in those ≥70 as 
compared to 3% < 40; p = 0.006)
For the same toxicities grade 3 or greater, the only category that varied with age was 
cardiovascular toxicity which increased with advancing age (6% for those ≥70 as compared 
to 1% <40; p = 0.019; Table 3). A Poisson model of the association of severe toxicity counts 
with age was developed (Supplemental Table 2)and age was not significantly associated with 
severe toxicity counts nor overall toxicities. Variables that were found to be associated with 
overall toxicities included body mass index (p = 0.0007), stage (p = 0.0137) and specific 
protocol (p < 0.0001). Of the 4 included studies, GOG protocol 219 was significantly 
associated with more severe toxicities as compared to the referent protocol which was GOG 
113 (HR 0.395 (0.715, 0.614)). Neither GOG 165 nor GOG 120 reported toxicities 
significantly different than those reported in GOG 113.
4.4. Outcomes
Age is significantly associated with OS (all-cause) and significantly nonlinear. Fig. 2 shows 
the partial effects plot of age on the log hazard ratio. The decrease in risk before age 50 
years is not significant given the wide confidence intervals, but after 50 the risk appears to 
increase sharply. The increase in risk is 2% (HR 1.02; 95% CI, 1.01–1.04) for every 1-year 
increase in age, with the other variables held constant. That is, patients in the age range >50 
years with a 1-year increase from a lower value have a 2% increase in risk of death from any 
cause.
However, multivariate analysis of age and disease-specific PFS and OS models found age 
was not significant in these models, indicating that the increase in risk of death was due to 
etiologies other than cervical cancer. Multivariate analysis did find that race (p = 0.0390), 
poor performance status (p = 0.0178), nonsquamous histology (p = 0.0009), size of tumor (p 
= 0.003), higher stage (p < 0.0001) and pelvic lymph nodes (p=0.0057) were all associated 
with disease specific progression free survival. Disease specific overall survival was only 
associated with race (p = 0.0185), lower performance status (p = 0.0032), non-squamous 
histology (p = 0.0121), stage (p < 0.0001), grade (p = 0.0299) and pelvic lymph nodes (p = 
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0.0010). Insurance status, or lack thereof, was evaluated and not found to be significantly 
associated with either all cause or disease specific survival. Race was only significant in that 
non-white, non-black patients had improved disease specific overall survival as compared to 
white patients while outcomes for black patients were indistinguishable from those of white.
5. Discussion
There is conflicting data on treatment and outcomes among older women with local–
regionally advanced cervical cancer. This disparity stems from the different populations 
studied. Here, we present an ancillary data analysis of 4, Phase I–III trials including over 
1300 women and demonstrate that there were not great differences in disease specific 
survival or toxicity when patients greater and <65 were treated in a standard fashion. 
Population based studies would suggest the opposite, that outcomes are worse and toxicities 
more severe with increasing age [6–8].
Our study did concur with the findings of several of these studies that treatments did differ 
with age – which is a surprising finding given that these patients were all enrolled on a 
clinical trial with standard treatment prescribed. The most concerning finding here was the 
absence of or incomplete intra-cavitary BT seen with increasing age that will be addressed 
below.
The demographics of cervical cancer among older women were nicely summarized by 
Sharma et al. in their SEER based analysis of treatment and outcomes for cervix cancer. In a 
cohort of over 28,000 women, 27% were diagnosed at age 60 or greater. These older women 
were more frequently non-White (p < 0.05) and more frequently had advanced disease (p < 
0.0001) [6]. Our study also demonstrated racial differences with age (p = 0.014) with more 
Hispanic and Asian women in the oldest age category but no differences in stage distribution 
(p = 0.14). Both of these later two points are likely entirely due to selection for the trials and 
don’t represent population based data.
In this analysis of over 1300 patients treated with CCRT, we demonstrated no difference by 
age in chemotherapy completion or chemotherapy delays. This reinforces the results Kunos 
et al. [4] reported including only patients on GOG-120 and 165 where he reported that after 
controlling for other clinical factors, patients age 55 and older were no more likely to stop 
protocol therapy early than those <55 years of age (OR 1.16; 95% CI 0.7–1.189; p = 0.552). 
Interestingly, his analysis did find that Black race was associated with failure to complete 
therapy as compared to Caucasian patients with an OR of 2.13; 95% CI 1.22–3.74; p = 
0.029) [4]. In looking at this population further, there were no toxicities or other factors that 
could explain this finding. In this analysis including both GOG-113 and 219, we find no 
association with treatment completion and race.
Radiation experience did appear to change with advancing age. We reported significantly 
more major radiation deviations in the oldest group; 27% in those ≥70 years of age as 
compared to 17% in those <40; p = 0.022. We don’t have details for these deviations but 
many of them may be related to the increasing rate of intracavitary BT (ICBT) omission 
with age. In our analysis, over 30% of patients >70 did not complete ICBT as compared to 
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13% in those <40; p <0.001. Although the importance of ICBT has been recognized for 
decades, the omission of ICBT in older patients has not been well reported until recently. 
Sharma et al. reporting from the SEER database found that use of ICBT declined with age 
from 66.7% in those <50 years old to 58.9% in those 70–79 and 46.3% in women >70 [6]. 
This translates into ICBT omission in 41% for those women 70 and older, which is not 
dissimilar to what our current study reports for women >65. Yanazume et al. evaluated 85 
patients with local-regional cervix cancer age 70–89. They categorized ICBT as complete, 
incomplete or impractical. Incomplete ICBT referred to discontinuation of otherwise 
technically feasible radiation delivery and impractical refers to technically challenging or 
infeasible delivery. In this cohort, 25% of patients could not receive or did not complete 
ICBT. Multivariate analysis found that non squamous cell cancer, incomplete ICBT and 
positive lymph nodes were all prognostic for PFS [20]. When they evaluated the 25% who 
did not receive or complete ICBT (n = 17), 15 of these were due to technical difficulty while 
only 2 were due to not proceeding with technically feasible delivery. In their analysis they 
found nulliparity (p = 0.014) and tumor size (p = 0.007) to both be independent predictors 
for failure to complete or receive ICBT [20].
Other authors have reported on ICBT completion with fairly consistent results (Table 4), the 
exception being Chakraborty reporting on a cohort of patients treated in Northern Kerala, 
India. This report was evaluating a new modality of external beam therapy so there may be 
selection bias here [21]. The more disturbing of the reports is the population based analysis 
by Sharma et al. where over 40% of patients >70 don’t receive ICBT for their cervix cancer 
[6].
In our current re-analysis of patients previously treated on GOG trials, we cannot know 
whether the deviations were due to technical feasibility or other reasons. One can postulate 
that, among a population of patients enrolled on a clinical trial, the reasons for incomplete 
intracavitary BT may well have been technical difficulties with using standard tandem and 
ovoids in older patients with vaginal stenosis and age related anatomic changes. Quality 
assurance for BT administered during participation in all 4 protocols included submission of 
orthogonal simulation films taken following intracavitary insertion. In addition, participating 
sites had to demonstrate the ability to achieve an accuracy of ±3% in measuring the output 
of their therapy units and ±5% in delivering prescribed dose. While the standards set for 
radiation administration were high, the analysis of the orthogonal simulation films is not 
available for this analysis and would be highly informative as to the question of whether BT 
was attempted or even feasible in some participants. It suggests the need to consider 
alternative strategies for BT administration as well as alternative coding should these 
strategies prove difficult.
Toxicities reported were not significantly different by age in this analysis with the exception 
of any grade lymphatic disorders that were more common with increasing age. Unlike prior 
analyses, there was no increase in the hematologic toxicities with increasing age. None of 
these studies allowed or included granulocyte stimulating factors as a part of their protocols 
so the reason for this is likely good patient selection for clinical trials in the older age ranges 
and more hematologic tolerance of therapies. Interestingly, toxicities did differ between the 
4 included studies with GOG 219 having 1.5 times as many reported severe toxicities as the 
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referent study GOG 113. It is unclear whether this result is real, or rather a result of 
improved toxicity reporting in this most recent Phase III trial.
As stated in the results, there was as association between increasing age >50 and all-cause 
mortality with an increased risk of 2% (HR 1.02; 95% CI, 10.1–10.4) for every 1-year 
increase in age with other variables held constant. When considering disease specific 
survival, however, age was not significant. This is similar to the findings of Kunos et al. 
which included some of this current population [4] but very different than population based 
analyses which find that women 70–79 years old (HR 1.12; 95% CI 1.01–1.24) and ≥80 
years old (HR 1.47; 95% CI 1.29– 1.68) with stage IIB–IVA disease were more likely to die 
of their cancers than younger women [6]. Other than disease specific characteristics such as 
tumor stage and presence of pelvic lymph nodes, the only other factors that appeared to 
impact disease specific survival were performance status and race. The impact of race, 
specifically black race on survival with cervical cancer has been well documented. In an 
analysis of linked US Census and SEER database information, black women with cervical 
cancer had a higher likelihood of dying from their disease as compared to white women even 
after adjustment for socioeconomic status (HR 1.09 (CI: 1.03–1.15)). Etiologies for this 
disparate survival are under investigation but include later stage at diagnosis and access to 
care among others [22]. Our study did not reproduce these findings as black women had 
survival outcomes that were indistinguishable from white patients. This is an encouraging 
finding and may be due to selection/enrollment bias of women, regardless of race, who have 
access to care centers with dedicated clinical trials programs in cervical cancer. Our analysis 
did look at insurance status as a surrogate for socioeconomic status and found no association 
with any of the endpoints under study, however, payer status may be a poor surrogate for this 
measure.
Our study demonstrates that in a selected population of older women treated on study, the 
toxicities were not meaningfully different with increasing age, completion of external beam 
did not differ and disease specific survival was similar. Somewhat disturbingly, we found 
that approximately 30% of patients enrolled on treatment specified trials failed to complete 
BT, mirroring what is seen in population-based data. With the increasing proportion of our 
population living into their 7th 8th and 9th decades and the bimodal distribution of cervical 
cancer incidence, we will see more of these older women with cervical cancer and we need 
to discern best practices. This group has been poorly studied in clinical trials and under 
treated based on population bases data. This has been attributed to multiple factors including 
physician bias, presence of multiple medical co-morbidities and a belief that elderly patients 
are more vulnerable and prone to toxicity [4, 7, 23]. The GOG launched a registration trial 
known as GOG-247, which was a prospective, multi-institutional observational trial 
evaluating baseline characteristics of patients who presented with treatment naïve cervical or 
uterine cancer and how these factors impact enrollment on a clinical trial. What was striking 
here is that patients over the age of 71 were less likely to have a trial available when 
compared with patients under the age of 41 (OR 0.4; 95% CI 0.2–0.8; p = 0.0097). This 
doesn’t mean these patients were ineligible, they were just being seen at a place where a trial 
wasn’t available. GOG-247 did note that multiple co-morbid illnesses were negatively 
associated with eligibility for a clinical trial (p = 00019) but this was not reported for age 
[24].
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This study is important and reassuring in showing that increasing age does not appear to 
result in increasing adverse effects among patients participating in GOG/NRG clinical trials. 
The problem is one of extrapolation to the general population. All patients participating in 
these studies met strict entry criteria (performance status; renal function; bone marrow 
function, et cetera) beyond just stage or absence of aortic lymph node involvement. It is 
anticipated that elderly women who have accumulated co-existing medical problems may 
have greater toxicity and less adherence to planned therapy. Future population-based studies 
will be important to determine whether age is an independent risk factor for adverse effects 
and/or poor outcome.
Supplementary data to this article can be found online at http://dx.doi.org/10.1016/j.ygyno.
2016.08.317.
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Box 1
Highlights
• Among older patients, toxicities and completion of chemo-RT for cervix 
cancer are not well defined.
• This ancillary NRG study demonstrates few differences in reported toxicities 
during chemo-RT by age.
• Brachytherapy was not completed in 35% of patients ≥70 as compared to 
13% of pts < 40.
• Disease specific survival did not differ among patients < 70 years old and 
those ≥ 70 years old.
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Fig. 1. 
Plot of the partial effect of age on the log odds of brachytherapy completion.
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Fig. 2. 
Plot of the partial effect of age on the log hazard ratio of overall survival (all cause) model.
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Table 4
Reported prevalence of incomplete intracavitary brachytherapy (ICBT) among older patients with cervical 
cancer.
Study Age n Incomplete
ICBT (%)
Explanation
Moore et al.
(2016)
>70 63 34.9% Not known
Yanazume et
al. (2014)
70–89 85 25% 88% due to technical issues
Chakraborty
et al.
(2014)
≥65 23 13% 2 pts. refused and 1 pt. had poor
response to tx
Sharma et al.
(2011)
(SEER)
70–79
≥80
1099
611
41.1%
53.7%
Other than age, predictors for ICBT
were race, year of diagnosis, area of
residence and stage
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